West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
West Pharmaceutical expands Dublin facility to boost injectable therapy capacity and strengthen its end-to-end manufacturing platform.
West Pharmaceutical Services, Inc. (WST) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
Cinctive Capital Management LP bought a new stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 14,319 shares of the medical instruments supplier's stock, valued at approximately $3,756,000. Other institutional
Brown Brothers Harriman and Co. lifted its holdings in West Pharmaceutical Services, Inc. (NYSE: WST) by 22.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 247,356 shares of the medical instruments supplier's stock after purchasing an
WST eyes growth from high-value components, GLP-1 drug demand and Annex 1 conversions, but generics destocking and European capacity constraints pose risks.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The mean of analysts' price targets for West Pharmaceutical (WST) points to a 32.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
West Pharmaceutical Services just sent investors $0.22 per share on February 4, 2026, marking the company's latest quarterly dividend payment.
West Pharmaceutical Services, Inc. (WST) Q4 2025 Earnings Call Transcript
West Pharmaceutical beats Q4 EPS and revenue estimates as proprietary products drive growth, while shares jump nearly 3.6% premarket on upbeat 2026 outlook.